|Bid||7.66 x 800|
|Ask||7.70 x 800|
|Day's Range||7.43 - 7.76|
|52 Week Range||6.02 - 10.26|
|Beta (3Y Monthly)||2.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 13, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.00|
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the 29th International Symposium on.
Cytokinetics, Incorporated (CYTK) today announced the first subject has been dosed in a Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple ascending dose clinical trial of CK-3773274 (CK-274) in healthy adult subjects. CK-274 is a novel cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM). “The start of clinical trials for CK-274 marks an important milestone in our continuing innovation of potential sarcomere-directed medicines,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he isn't a fan of Netflix, Inc. (NASDAQ: NFLX ) because the content isn't as compelling as it once was. He sees it as a good story, but ...
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Cytokinetics, Incorporated (CYTK) today announced the completion of patient enrollment in FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial designed to assess the change from baseline in the percent predicted slow vital capacity (SVC) and other measures of skeletal muscle function after 12 weeks of treatment with reldesemtiv (formerly CK-2127107). In collaboration with Astellas Pharma Inc. (TSE:4503) (“Astellas”), Cytokinetics is developing reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA), as a potential treatment for people living with debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced five poster presentations at the 29th International Symposium on ALS/MND in.
Cytokinetics, Incorporated (CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13, 2018 at 10:20 AM MT at The Phoenician in Scottsdale, AZ, and to participate in a Fireside Chat at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 10:00 am ET at the Lotte New York Palace in New York. Additionally, members of Cytokinetics’ senior management team will also participate in the Global Mizuho Investor Conference on December 3-4, 2018 at the Lotte New York Palace in New York. The webcast replay of each presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of the event.
Cytokinetics (CYTK) delivered earnings and revenue surprises of 24.53% and 377.18%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of 40 cents. The biopharmaceutical company posted revenue of $10.6 million in the period. Cytokinetics shares ...
METEORIC-HF Advancing to Trial Initiation FORTITUDE-ALS on Track to Complete Enrollment by Year End Phase 1 Clinical Studies of CK-274 and AMG 594 To Start in Q4 SOUTH SAN.
Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report third quarter results on November 1, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.
Cytokinetics, Incorporated (CYTK) plans to present an expansion of its development pipeline with the progression of two additional cardiac muscle directed drug candidates towards first-in-human clinical trials, at an R&D Day today in New York. The first, a novel cardiac troponin activator, discovered under its joint research program with Amgen, was the subject of an Investigational New Drug Application (IND) that Amgen recently filed with the Food & Drug Administration (FDA).
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...
Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today provided an update for their collaborative skeletal muscle program, including clinical trial updates for reldesemtiv in neuromuscular and non-neuromuscular conditions. In addition to reldesemtiv, the companies are advancing another fast skeletal muscle troponin activator (FSTA) into Investigational New Drug (IND)-enabling studies and continuing their joint research program through 2019. Cytokinetics has been developing reldesemtiv as a potential treatment for people with Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), and other debilitating neuromuscular diseases and conditions associated with skeletal muscle weakness and/or fatigue.
Cytokinetics, Incorporated (CYTK), today announced that it will host an R&D Day on Tuesday, October 16, 2018 from 8:30 AM to 12:30 PM ET at the Parker New York Hotel in New York City. Members of Cytokinetics’ senior management will be joined by expert clinicians to provide new updates to the pipeline and review current clinical programs.
If you’re interested in Cytokinetics Incorporated (NASDAQ:CYTK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018-- Cytokinetics, Inc. today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Cantor Fitzgerald ...
Cantor Fitzgerald has high hopes for patients with rare and orphan diseases. “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said ...
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
Biopharma Cytokinetics Inc. (NASDAQ: CYTK ) announced a delay in drug studies during its earnings call Thursday, prompting a downgrade by Morgan Stanley. The Analysts Morgan Stanley's Matthew Harrison ...